Get the Stockscreener App
0.5921
1.32%
-0.0079
Pre-market:
.60
0.0079
+1.33%
Psyence Biomedical Ltd stock is traded at $0.5921, with a volume of 44,843.
It is down -1.32% in the last 24 hours and down -52.25% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$0.60
Open:
$0.605
24h Volume:
44,843
Relative Volume:
0.13
Market Cap:
$2.68M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.18%
1M Performance:
-52.25%
6M Performance:
-90.95%
1Y Performance:
-99.31%
1-Day Range:
$0.57
$0.605
1-Week Range:
$0.57
$0.696
52-Week Range:
$0.57
$108.00
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
0.5921 | 2.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Psyence Biomedical reports corporate update By Investing.com - Investing.com South Africa
Psyence Biomedical reports corporate update - Investing.com
Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView
Psyence's Game-Changing Phase IIb Trial Takes On Cancer Mental Health Crisis - Stock Titan
Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times
Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World
Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia
Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - TradingView
Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times
Psyence Biomedical files to sell 13.81M common shares for holders - MSN
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com
Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire
Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan
Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater
Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks
Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World
Psyence enters into $25M common stock purchase agreement with White Lion Capital - MSN
Psyence Biomedical Issues Pre-Funded Share Purchase Warrant - TipRanks
Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times
Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan
Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance
Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Unveils Private Placement - Baystreet.ca
Psyence Biomed announces $2 million private placement - Investing.com
Psyence Biomed Announces $2.0 Million Private Placement - The Manila Times
Psyence Biomed Secures $2M Private Placement with Strategic Warrant Offering - StockTitan
Psyence Biomedical Achieves Full Nasdaq Compliance, Advances Clinical Trial Plans with $5.6M War Chest - StockTitan
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone' - Benzinga
Psyence Biomedical Signs Exclusive Licensing Agreement with Optimi Health - TipRanks
Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial - TipRanks
Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial - The Manila Times
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial - Newsfile
Psyence Biomedical executes binding agreements with Optimi Health - Yahoo Finance
Psyence Biomedical stock soars on binding agreements with Optimi Health - MSN
Psyence Biomed Executes Binding Agreements with Optimi Health Corp - Marketscreener.com
Psyence Biomed Executes Binding Agreements with Optimi Health Corp. - The Manila Times
Psyence Biomedical Ltd Stock (PBM) Financials Data
There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):